The Market Reports

Synopsis

The global market for Human Microbiome was estimated to be worth US$ 568 million in 2024 and is forecast to a readjusted size of US$ 3351 million by 2031 with a CAGR of 30.5% during the forecast period 2025-2031.

The Human Microbiome refers to the collective microorganisms and their genetic material residing in various parts of the human body, such as the gut, skin, mouth, respiratory tract, and reproductive system. These microbes form a symbiotic relationship with the human host, playing critical roles in immune modulation, nutrient absorption, metabolic regulation, and disease prevention. With the advancement of high-throughput sequencing, synthetic biology, and artificial intelligence, the commercialization of the microbiome is shifting from basic research toward precision medicine, immunotherapy, probiotics, functional foods, and personalized nutrition. The global human microbiome industry is now entering an accelerated application phase, becoming a model for cross-border integration across healthcare, biotechnology, and nutrition sectors, and attracting major pharmaceutical and biotech companies, as well as emerging startups.

The human microbiome sector has gained momentum due to rising demand for precision medicine, chronic disease management, and alternatives to antibiotics. Increasing evidence from Phase III clinical trials supports the role of gut microbiota in conditions such as cancer, neurological disorders, and autoimmune diseases, accelerating product development in therapeutics, diagnostics, and nutritional interventions. The U.S. and EU have included microbiome initiatives in their national-level precision medicine strategies, and investor interest continues to surge. The global market for microbiome therapeutics is projected to surpass $10 billion by 2030.

Despite the promising outlook, the industry faces significant hurdles. These include individual microbiome variability leading to inconsistent treatment efficacy, lack of standardized clinical validation pathways, and regulatory uncertainty. Technological challenges around scalable manufacturing, storage, activity control, and genomic safety further complicate commercialization. Additionally, public acceptance, ethical concerns, and low physician familiarity with microbiome-based therapies present barriers to market expansion.

Downstream, pharmaceutical, nutritional, and diagnostic companies are accelerating commercialization of microbiome-related products. There is growing demand for gut microbiome therapeutics, fecal microbiota transplantation (FMT), probiotics, and next-generation probiotics (NGPs), particularly in cancer support therapy, autism management, and inflammatory bowel disease. Rising consumer awareness of microbiome balance is also fueling demand in functional food and personalized nutrition, turning the sector into a hotbed for venture capital and strategic investment.

This report aims to provide a comprehensive presentation of the global market for Human Microbiome, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Human Microbiome by region & country, by Type, and by Application.

The Human Microbiome market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Microbiome.

Market Segmentation

By Company

• Vedanta
• Seres Therapeutics
• Second Genome
• Rebiotix
• ActoGeniX
• Enterome BioScience
• AvidBiotics
• 4D Pharma Research Ltd
• Enterologics
• Metabogen
• Metabiomics
• Ritter Pharmaceuticals
• Osel
• Symberix
• Miomics
• Symbiotix Biotherapies
• MicroBiome Therapeutics LLC

Segment by Type

• Gastrointestinal Tract Human Micobiome
• Urogenital Tract Human Micobiome
• Others

Segment by Application

• Treatment
• Diagnosis

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.